Patient-Derived Xenograft Models for Endometrial Cancer Research

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
Carboplatin 4 endocrinologydiseasesdrugs
endometrial carcinoma 5 endocrinologydiseases
sorafenib 5 endocrinologydiseasesdrugs

Graph of close proximity drug and disease terms (within 200 characters).

Note: If this graph is empty, then there are no terms that meet the proximity constraint.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
Carboplatin 29743 Moreover, when combining both therapies, NVP-BEZ235 and AZD6244, the treatment was as effective as Carboplatin , resulting in disease stabilization showing no increment of tumour growth.All of the above-mentioned
Carboplatin 32505 tissue in vivo. Moreover, MRK-003 treatment augmented the anti-tumour activity of standard Paclitaxel/ Carboplatin (P/C) therapy in one of the two primary human PDX models. The observed synergistic effect of MRK-003
Carboplatin 42768 fragment60–80%2–3 monthsAthymic nude4043%EEC; 32%PS; 10%CS; 2.5%CC; 5%undifferentiated 7.5%other types Carboplatin Paclitaxel, Palbociclib (60)KULPrimary tumor, metastases, recurrencesheterotopic (s.c)8–10 mm3 tissue
Carboplatin 42977 tissue fragment100%3–5 monthsAthymic nude1546%EEC; 13%PS; 13%CS; 7%undifferentiated 21%other types Carboplatin , NVP-BEZ235, AZD 6244 (33)HUHBPrimary tumor, metastasesorthotopicCell suspension25–100%3–13 monthsNSG560%EEC;
sorafenib 30517 demonstrated moderate effects. In a recent work, Eritja et al. [[61]] studied the resistance mechanism of sorafenib in EC and demonstrated that autophagy acted as a protective mechanism against sorafenib. They developed
sorafenib 30605 mechanism of sorafenib in EC and demonstrated that autophagy acted as a protective mechanism against sorafenib . They developed in vitro assays and three different endometrial orthotopic xenografts (endometrioid
sorafenib 30816 EC grade 1, 2, and 3), and observed that the inhibition of autophagy by using cloroquine potentiates sorafenib effects in PDX orthotopic EC tumours. These results provided insights into the modest effects of sorafenib
sorafenib 30923 sorafenib effects in PDX orthotopic EC tumours. These results provided insights into the modest effects of sorafenib trials in EC patients and might open new avenues for the design of preclinical studies using sorafenib.Equally
sorafenib 31026 sorafenib trials in EC patients and might open new avenues for the design of preclinical studies using sorafenib .Equally important is the discovery of biomarkers to predict treatment-response, as this will help to
Select Disease Character Offset Disease Term Instance
endometrial carcinoma 9404 dualistic model according to its biological, molecular, and clinical features. Type I or endometrioid endometrial carcinoma s, comprising 80% of cases, are mainly represented by low-grade and hormone-receptor-positive tumours,
endometrial carcinoma 9562 mainly represented by low-grade and hormone-receptor-positive tumours, while type II or non-endometrioid endometrial carcinoma s are represented by papillary serous carcinoma, clear cell carcinoma, and carcinosarcoma, among other
endometrial carcinoma 10672 grade, stage, and myometrial and lymphovascular invasion [[26]]. Nonetheless, 8% to 10% of early stage endometrial carcinoma develops recurrence and distant metastasis. Current classification systems have a limited potential
endometrial carcinoma 41234 tumour evaluation. Bioluminescence imaging (BLI) enables the monitoring of cell-line-based orthotopic endometrial carcinoma , here demonstrated in a xenograft model generated from luciferase expressing Ishikawa cells (L). 18F-FDG
endometrial carcinoma 41408 from luciferase expressing Ishikawa cells (L). 18F-FDG PET/CT imaging is well suited for detection of endometrial carcinoma in PDX-models (R). Uterine tumours were confirmed by necropsy for each respective model (bottom).Figure

You must be authorized to submit a review.